(2 intermediate revisions by the same user not shown)
Line 56:
Line 56:
font-family:'DIN B','DIN Medium';
font-family:'DIN B','DIN Medium';
}
}
−
+
h1, h2, h3, h4, h5, h6{
+
overflow:auto !important;
+
padding: 1rem 0 !important;
+
}
+
p{
+
margin:0 !important;
+
}
html,
html,
body,
body,
Latest revision as of 03:32, 22 October 2019
Team
Project
Lab
Model
Parts
HP
Judging
Home
Members
Collaborations
Attributtions
Background
Description
Design
Result
Demonstrate
Notebook
Protocols
Safety
Model
Our parts
Improvement
Measurement
Integrated
Engagement
Juding Form
Medals
What's VVC?
Vulvovaginal candidiasis (VVC) has been recognized as one of the most common infections in female reproductive organs.
VVC is mainly caused by Candida albicans (C. albicans), accounting for more than 85% of the incidence, which seriously affects the normal life of women.
70-75%
of women will suffer from VVC at least once in thier life time.
40-45%
will have 2 or more episodes.
Symptoms
Abnormal Vaginal Discharge
Genital and Vaginal burning
External Dysuria
Itching and Redness
How to Treat?
Till now, as a commonly used antifungal drug for VVC treatment, vaginal azole preparations can inhibit the growth of C. albicans, or kill them directly.
HOWEVER
The widespread usage of antifungal drugs and the increase in the number of fungal infections have led to the emergence of drug resistance, even the repeated recurrence to VVC of patients.
Our project is well conducted by Model in terms of experiments and prediction of future application. Our Model is constituted with1. C. albicans Sensing Model2. Gene Concentration Prediction Model3. Market Prediction Model